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α Alpha  
α-Glycerol-P Alpha-Glycerol-Phosphate  
ACAT-2 Acetyl-Coenzyme A acetyltransferase 2 
ACE-I 
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Angiotensin Converting Enzyme Inhibitor 
American Diabetes Association  
AGE Advanced Glycation End-products 
AIDS Acquired Immunodeficiency Syndrome  
ALE Advanced Lipoxidation End-products                                                                                                                                               
AlipoB Alipoprotein-B 
AMP Adenosine Monophosphate 
AMPK Adenosine Monophosphate-Activated Protein Kinase 
ANG II Angiotensin II 








Blood Pressure  
BW Body Weight                                                                                                                                                                                                                         
Ca2+ Calcium ions 
cAMP Cyclic Adenosine monophosphate-phosphodiesterase 
CETP Cholesterol Ester Transfer Protein 





CTS Carpal Tunnel Syndrome 
CYP3A4 Cytochrome P450 3A4 
D60 Diabetic, 60 mg/kg 
DAG 1, 2~diacylglycerol 
δ Delta 
DHA Decosahexaenoic Acid 
DHAP Dihydroxyacetone Phosphate 
DKA Diabetic Ketoacidosis  
DM Diabetes Mellitus  
DPP Dipeptidyl Peptidase 
EDTA Ethylenediaminetetraacetic Acid                                                               
EPA Eicosapentaenoic Acid  
ESRD End-of Stage Renal Disease  
ESRF End-of Stage Renal Failure 
FBG Fasting Blood Glucose  
FFA Free Fatty Acid 
Fructose-6-P Fructose-6-Phosphate 
γ Gamma                                                                          
GAD Glutamic Acid Decarboxylase             
GAPDH Glyceraldehyde 3-Phosphate Dehydrogenase 
GFAT Glutamine:Fructose-6-phosphate Amidotransferase 
GFJ Grapefruit Juice 
GFJ-D60 Grapefruit juice and Diabetic, 60 mg/kg 
GFJ-ND Grapefruit juice and non-diabetic 













H2SO4 Sulfuric Acid 
HbA1c Glycosylated haemoglobin 
HBP Hexosamine Biosynthesis Pathway 
HDL High Density Lipoprotein  
HDL-C High Density Lipoprotein Cholesterol 
HEPES 4-(2-Hydroxyethyl)-1-Piperazineethanesulfonic Acid 
HIV Human Immunodeficiency Virus                                                                                  
HMG-CoAR 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase 
IDDM Insulin-Dependent Diabetes Mellitus 
IDP Inositol Diphosphate 
Ins-D60 Insulin and Diabetic, 60 mg/kg;  
K+ Potassium  
KCl Potassium Chloride  
Km 1/slope 
KOH Potassium Hydroxide  
LADA Latent Autoimmune Diabetes in Adults 
LDL Low Density Lipoprotein  
LDL-C Low Density Lipoprotein Cholesterol 





MgCl2 Magnesium Chloride  
MODY Maturity Onset Diabetes of the Young      
Na+ Sodium 
Na2CO3 Sodium Carbonate 
NAD Nicotinamide Adenine Dinucleotide 
NADH Nicotinamide Adenine Dinucleotide Hydride  
NADP+ Nicotinamide Adenine Dinucleotide Phosphate 
NADPH Nicotinamide Adenine Dinucleotide Phosphate Hydrogen                                                               
NIDDM Non-Insulin-Dependent Diabetes Mellitus 




Nitric Oxide Synthase 
Oxaloacetate 
Organic Anion-Transporting Protein 





Polycystic Ovary Syndrome 
Phosphoenolpyruvate carboxykinase 
PKC Protein Kinase C 
PPAR Peroxisome Proliferator-Activated Receptor 
RAPD Random Amplified Polymorphic DNA  
RAS Renin-Angiotensin System 
RBT Random plasma (Blood) glucose Test 
ROS Reactive Oxygen Species                                                                                                                                      
SCAR Sequence Characterized Amplified Region 





SDS–PAGE Sodium Dodecyl Sulphate Poly Acrylamide Gel Electrophoresis 
STZ Streptozotocin 
SUR Sulfonylurea Receptors 
TB Tuberculosis                                                          
TG Triglycerides  
TZD Thiazolidinedione 
UDP Uridine Diphosphate 
UDP-GlcNAc Uridine Diphosphate- N-acetyl glucosamine 
UNE Ulnar Neuropathy at the Elbow 
VEGF Vascular Endothelial Growth Factor 
VLDL Very Low Density Lipoprotein  
Vmax Maximum Velocity  
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Hypoglycaemic effects of grapefruit juice in diabetic rats have been previously reported. The 
mechanisms by which grapefruit juice lowers blood glucose are not known. This study aimed 
to investigate the hypoglycaemic and anti-dyslipidaemic effects of grapefruit juice, as well as 
to elucidate the possible mechanism/s of action of this juice.  
Materials and Methods 
Male Wistar Rats (Rattusnovergicus) of 200-300 g body weight (BW) were randomly divided 
into five groups (n=6). Animals in group 1 were treated with 3.0 ml/kg of water for 60 days, 
by oral gavage. Groups 2, 4 and 5 were rendered diabetic by a single intraperitoneal injection 
of 60 mg/kg BW of streptozotocin. Group 5 was further treated with 4.0 U/kg of insulin 
(subcutaneously, twice daily), while groups 3 and 4 were orally treated with 3.0 ml/kg of 
GFJ.  
Fasting blood glucose and glucose tolerance tests were done in all the groups. Plasma insulin 
levels were also measured. Hepatic glycogen content, glucokinase and glucose-6-phosphatase 
(G6Pase) activities were measured in homogenised liver tissues. Plasma lipid levels were 
measured and hepatic enzymes (Acetyl-Coenzyme Aacetyl Transferase (ACAT) and 3-
Hydroxy-3-Methyl-Glutaryl-CoA (HMG-CoA reductase) expression was determined.  
Results 
Diabetic rats showed significantly reduced weight gain, but higher water consumption in 
comparison to the controls. Fasting blood glucose was significantly higher in the diabetic 
group compared to controls, but were significantly (p<0.05) attenuated in GFJ-treated 





glucose tolerance compared to controls, which was, however, improved in GFJ-treated 
groups in comparison to the diabetic non-treated group. GFJ treatment did not improve 
fasting plasma insulin in diabetic animals. Glucokinase activity and hepatic glycogen 
concentrations were significantly increased by GJF treatment, but G6Pase was alternatively 
suppressed by GFJ treatment. HDL-C levels were significantly increased in GFJ treated 
diabetic animals. Liver ACAT and HMG-CoA reductase enzyme expression were 
significantly suppressed in GFJ treated diabetic animals in comparison to the non-treated 
diabetic animals.  
Conclusion 
The findings show that GFJ has both hypoglycaemic and anti-dyslipidaemic effects. 
Although it not insulinotrophic, GFJ improves glucose intolerance in diabetic animals by 
supressing hepatic gluconeogenesis. Furthermore, GFJ improved plasma lipid profiles and 
supressed the liver expression of ACAT and HMG-CoA reductase enzymes.  
Key words: grapefruit juice, diabetes mellitus, diabetic dyslipidaemia, insulin, lipids, ACAT, 







Literature Review and Introduction 
1.1 Epidemiology of diabetes mellitus 
Diabetes Mellitus is a metabolic disorder with genetic, environmental or acquired causes [1-
3], and is characterised by chronic hyperglycaemia as well as altered carbohydrate, protein 
and fat metabolism [4, 5]. These result from insulin resistance, the inability of the body to 
produce insulin, or the combination of both [6].Diabetes usually presents itself with a cocktail 
of symptoms such as excessive thirst, blurring of vision, polyuria and weight loss [4]. These 
symptoms are sometimes not severe, and may at times even be absent, but the 
hyperglycaemia present may be enough to cause both pathological and functional changes, 
which may be present when the diagnosis is made [4]. Diabetes is classified into four main 
classes namely Type1, previously known as Insulin-Dependent Diabetes Mellitus (IDDM),  
Type 2previously known as Non-Insulin-Dependent Diabetes Mellitus (NIDDM), gestational 
diabetes and other specific types [7]. Type 2 diabetes is the most prevalent diabetes 
worldwide [5, 7, 8].Other types of diabetes include a varied group of conditions which may 
be of genetic, surgical, malnutrition and infections origins, which may lead to symptoms and 
manifestations of diabetes [7]. Maturity Onset Diabetes of the Young (MODY), is classified 
under other specific types of diabetes [7, 9].  
It was predicted that the prevalence of diabetes worldwide would reach 150 million people in 
the year 2000; and this number was expected to double to 300 million people by the year 
2010 [8, 10]. By the year 2025 it is predicted that type 2 diabetes alone will be affecting more 
than 300 million people worldwide [11]. Increased longevity and urbanisation, lifestyle 





Type 2 diabetes [8, 9]. In the 1980‘s, there was very little epidemiological data on diabetes in 
the continent of Africa [12-15], with most data in the 1980‘s indicating diabetes prevalence 
of between 0% -1.4% in Africa [10, 14, 15]. The reports of the incidences of diabetes in the 
continent of Africa have in the past two decades changed, with diabetes presenting itself as a 
significant medical problem in the developing countries of Africa [10].   
Diabetes in Africa 
From the low diabetes prevalence of between 0% to 1% observed among Africans in the 
1980‘s, the diabetes burden reached 20% in the 2000‘s, and is predicted to be affecting 
between 18.6 to 23.9 million Africans by the year 2030 [13, 14]. This would be a 98% rise 
from the 12.1 million seen in 2010 [13]. In African countries, diabetes has a higher 
prevalence in urban areas, where there is low physical activity, and where people indulge 
more in diets high in fat and sugars [9, 14]. Furthermore, obesity, one of the greatest 
contributing factors of diabetes [9],  is very high Africa, with equal prevalence among all 
ethnic groups and age groups, but a higher prevalence among females than males [14]. There 
is also evidence of the racial predilection in the number of individuals suffering from diabetes 
[10, 13-15]. In most African countries, such as Kenya, Mali, Mozambique, Zambia and 
Nigeria; Africans of European descent are most affected by diabetes, followed by Indians and 
finally by Blacks. This racial predilection is attributed to genetic causes [14].  
In South Africa, like most African countries, there is a rural-urban gradient that is observed in 
the prevalence of diabetes. In the year 2000, the South African National Burden Disease 
Study reported that diabetes was the tenth leading cause of morbidity and mortality in South 
Africa, accounting for about 2.6% of all deaths, which represents to 20000 deaths, (4.3%) of 
the South African population [16]. However, these estimates may be lower than current 





The burden of diabetes in South Africa and Africa holistically is far too high, and 
improvements in treatment/management strategies as well as preventive measures that can 
delay the onset of diabetes should be employed [16]. One of the greatest challenges in the 
management of diabetes and other pandemics in Africa at large is the burden of these 
diseases, in comparison to the technology and the cost of managing these diseases [13, 14, 
16]. Hence, more inexpensive yet effective strategies to reduce the burden of diabetes should 
be employed. Such strategies include, over and above current approaches, the use of plant 
and plant materials in the prevention, treatment and possibly cure of diabetes.   
1.2 Pathogenesis of diabetes 
1.2.1 Blood glucose homeostasis 
The endocrine pancreas contains three different types of secretory cells which function in the 
secretion of glucagon (α-cells), insulin (β-cells) and somatostatin as well as gastrin (δ-cells) 
[17]. The secretion of insulin promotes the uptake of glucose, amino acids and fatty acids. It 
also increases glycogen synthesis and storage in the liver from glucose [17]. Somatostastin 
functions in the regulation of the release of insulin and glucagons, decreasing the motility of 
gastrointestinal tract and growth hormones secretion [17]. During the fed state, carbohydrates 
are broken down into glucose, fructose and galactose by gastrointestinal tract enzymes [17]. 
These sugars are then actively and passively absorbed, and transported by transporters from 
epithelial cells into capillaries. Once the glucose reaches the blood stream, it is taken up into 
pancreatic cells. The increased concentration of glucose inside pancreatic cells stimulates the 
release of insulin, which then diffuses into the portal vein, where it is transported by the 
blood into the liver at the same time with digested food [5, 17]. Insulin thus secreted acts on 
tissues that store energy, such as the liver, skeletal and adipose tissues [5]. During fasting 





pancreatic β-cells reduce the amount of insulin secreted [5]. Glucagon then mobilizes glucose 
from the liver by increasing glycolysis and gluconeogenesis. When the individual continues 
with fasting, catecholamine and glucocorticoid concentrations increase, leading to the release 
of fatty acids; the break-down of protein and adipose tissues [17]. 
It is critical that plasma glucose concentrations be maintained, as it is an energy source for 
delicate organs like the Central Nervous System (CNS) [5]. The CNS cannot produce nor 
store glucose for long periods and the smallest levels of hypoglycaemia can cause drastic 
CNS dysfunctions. To prevent for CNS dysfunction as a result of hypoglycaemia, glucose 
regulatory systems have evolved to reduce hypoglycaemia. Under normal conditions, plasma 
glucose concentrations are maintained at a narrow range of between 3 and 5.5 mmol/L [5, 7]. 
This range is maintained by insulin that is secreted from beta cells of the pancreas [7], in spite 
of variations in glucose levels that occur after meals and exercise [5]. Fasting blood glucose 
levelsabove6 mmol/L are associated with the progression of diabetes [7]. 
1.2.2 Diagnosis of diabetes mellitus 
Diabetes Mellitus is diagnosed using one or a combination of the following methods, which 
primarily measure glycaemia [9]. The three major tests used to measure blood glucose levels 
include the Random Blood glucose Test (RBT), Fasting Blood glucose Test (FBG), as well as 
the two hour post glucose load Oral Glucose Tolerance Test (OGTT) [5, 7, 9]. The presence 
of diabetes is diagnosed by glucose levels of greater than 11.0 mmol/L for RBT, in 
combination with symptoms of diabetes [5, 7, 9] and >7.0 mmol/L  for the FBG, according to 
the American Diabetes Association (ADA) criteria [5]. In OGTT, diabetes is diagnosed by 
blood glucose levels greater than 11 mmol/L, after two hours post ingestion of 75 g of 
glucose, diluted in water [5, 18, 19]. The OGTT is not always a necessity, except during 
pregnancy, or for patients who are thought to be diabetic but diabetes unconfirmed using 





Glycosylated haemoglobin (HbA1c) is a test that is used to measure the level of glucose 
control[5]. Elevated blood glucose levels bind to the amino-terminal valine of the 
haemoglobin β-chain, progressively and permanently; hence the measurement of HbA1c 
assists in determining the level and quality of glucose control over time [5]. Red blood cells 
have a long half-life120 days [7]; hence the percentage of HbA1c is the measure or index of 
glucose concentration for the preceding eight weeks, with normal values set to be between 4 
to 6% [5, 7]. Values of between 10 to 12% are suggested to reflect poorly controlled glucose 
levels and treatment goals aim for values of less than 7% HbA1c [19]. The HbA1c test is, 
however, suggested to have limitations as the observed results can be affected and lowered by 
diseases such as renal disease and anaemia, or any other disease types that affect the life or 
longevity of red blood cells [7]; hence often not preferred over blood glucose tests [18]. Other 
limitations of the HbA1c is that it is not very sensitive and is very expensive [19]; however, it 
is confirmatory [5, 7, 19].    
Urine glucose tests measure the amount of glucose present in the urine, using reagents or 
dipsticks [5]. These tests are, however, thought to be cumbersome and their results are 
loosely interpreted as they are prone to many factors [5]. Urine ketone tests use the 
nitroprusside reaction to test for acetoacetate, however, do not measure β-hydroxybutyrate 
(which is a major ketone in type 1 diabetic individuals) [5]. Therefore, when ketones are in 
the form of β-hydroxybutyrate, the urine ketone test may yield negative results in patients 
with ketosis [5]. These tests may at times be used in combination in order to get accurate 
results.  
1.2.3Type 1 diabetes 
Type 1 diabetes is a partially immunologically-mediated disease [4, 20] and is caused by the 
destruction of islet β-cells in the pancreas [20]. The destruction of the β-cells ultimately 





complications such as ketoacidosis, which is associated with low blood pH, profound 
electrolyte imbalance, resulting from a combination of elevated glucagon levels and insulin 
deficiency [5]; coma and even death if insulin is not administered [4]. Low or no insulin 
secretion, is often accompanied by untraceable levels of the C-peptide in the plasma [4].  
Insulin signalling causes the translocation of the glucose transporter-4 (GLUT4) to the 
plasma membrane, allowing for glucose to enter the β-cells [4, 21]. The absence or lack 
insulin results in the absence of GLUT4 translocation, resulting in reduced or no glucose 
uptake within the cell. The process of beta cell destruction may at times be detected without 
any metabolic abnormalities or before the disease is manifested clinically [4, 22]. The 
presence of insulin, β-cell as well as anti-glutamic acid decarboxylase (anti-GAD) antibodies 
are usually used to identify the autoimmune processes that lead to the destruction of beta cells 
and progression of Type 1 diabetes [4]. The rate of beta cell destruction differs among 
different patients, but has been observed to be faster in children and slower in adults [4, 22, 
23].  
The slow progression of beta cell destruction, present mainly in adults is known as Latent 
Autoimmune Diabetes in Adults (LADA). In some patients, particularly children and 
teenagers, the disease‘s first clinical manifestation is the presence of ketoacidosis. Others 
may have modest hyperglycemia, which in the presence of other diseases may change rapidly 
to severe hyperglycemia, and sometimes ketoacidosis [4]. However, some patients, more so 
adults, may retain some functionality of their beta cells and not develop ketoacidosis for 
many years [4]. Ultimately all Type 1 diabetes patients become dependent on insulin and are 





1.2.4 Type 2 Diabetes 
Type 2 diabetes, also known as the insulin independent form of diabetes, is adult onset,  and 
individuals suffering from it usually display insulin resistance [4, 18]. The exact and specific 
causes of Type 2 diabetes are not well defined, but are thought to be a combination of 
genetic, environmental as well as life style factors[4, 24].Type 2 diabetes commonly remains 
undiagnosed because the hyperglycaemia remains latent [4], and is often only diagnosed 
during tests or after the disease has progressed as far as causing polyuria or polydipsia[18, 
19]. Type 2 diabetes is diagnosed using the FBG, two hour OGTT, the random blood glucose 
test as well as the HbA1c test [19], in combination or individually. The disease is 
characterised by insulin resistance in peripheral tissues, particularly muscle and fat, but also 
in the  liver, leading to increased secretion of insulin and eventually β-cell failure [25]. 
Insulin resistance often results from obesity and sedentary lifestyle [7, 26]. Both insulin 
receptor and insulin post-receptor signalling defects have been reported in the progression of 
insulin resistance, but the primary cause between the two is still unclear [7, 21]. Pancreatic β-
cells compensate for insulin resistance for some time, but in some patients the pancreatic 
cells fail to keep up with the demand for insulin [21]. Although non-diabetic obese 
individuals are prone to developing insulin resistance and diabetes, some patients who are 
obese may never develop diabetes, because their β-cells secrete insulin enough to compensate 
for increased glucose levels [27].In general, Type 2 diabetes patients have circulating insulin 
levels, but these are often not enough to overcome the insulin resistance in target tissues. This 
insulin resistance thus result in the loss of β-cells by apoptosis [9, 21]. This then results in 
defective insulin secretion, particularly in response to post prandial glucose stimuli [9], which 
leads to imbalances between insulin action and hormones that regulate it [21]. The resulting 
outcomes of these imbalances are hyperglycaemia and dyslipidaemia, as well as inappropriate 





Genetic defects can lead to obesity, insulin resistance as well as pancreatic β-cell failure[25-
27], and may be monogenic or polygenic [9]. Mature Onset Diabetes in the Young (MODY) 
results from early β-cell failure, which genetically is caused by an inherited gene mutation in 
Hepatic nuclear factor-4 [9, 21]. The fact that some diabetic patients do secrete insulin, 
suggests that Type 2 diabetic individuals can be treated with orally available medications that 
function to (i) slow down the absorption of sugars in the gastro intestinal tract, thereby 
reducing blood glucose levels (ii) increase the amount of insulin released by the pancreatic 
cells and (iii) sensitize or make sensitive target cells to the action of insulin [21]. Due to the 
aetiology of this disease being multi-factorial, it is most probable that the number of people 





1.3 Aetio-pathogenesis of diabetes mellitus 
The core causes of diabetes mellitus are not certainly known, but a number of processes 
involved in its aetiology are known [3, 4]. Such processes are those involved in the 
destruction of beta cells of the pancreas, consequently leading to insulin deficiency, as well as 
other processes that result in the resistance of insulin action [4]. Insulin deficiency or insulin 
insensitivity leads to carbohydrate, protein and fat catabolism, as a result of the deficient 
action of insulin on target tissues [4, 5].  
Hyperglycaemia, which is the main feature of diabetes, leads to a number of metabolic 
derailments in diabetic patients [19, 29, 30]. Hyperglycaemia causes alterations in the 
Na+/Ca2+ ion channels resulting in elevated Ca2+ intracellular concentrations [29], and also 
increased production of free radicals and their intermediates, which produce highly glycative, 
glycoxidative, carbonyl compounds leading to oxidative stress. These play important roles in 
the pathogenesis of diabetes [31]. These free radicals are formed as a result of Advanced 
Glycation End-products (AGE) formation, the polyol pathway as well as the activation of 
protein kinase C and the hexosamine pathway [19], which are the mechanisms by which 
hyperglycaemia induced damage leads to complications in diabetes [19, 30].  
1.3.1 Advanced Glycation End-products (AGE) pathway 
Advanced Glycation End-products (AGE‘s) are defined as a varied group of compounds 
which occur as a result of the non-enzymatic reactions of free amino groups such as lipids, 
proteins and nucleic acids, with reducing sugars [31, 32]. AGE‘s function by cross linking 
proteins of the vessel wall, resulting in the thickening and leakage of the vasculature [29]. 
AGE formation results in plasma proteins binding to AGE receptors on endothelial cells, 
leading to the formation of Reactive Oxygen Species (ROS), [18, 30, 33], which impair 
cellular interactions, and also cause damage to vascular function, resulting in endothelial 





1.3.2 Protein Kinase C (PKC) pathway 
Protein Kinase C (PKC) is a cytoplasmic phospholipid–dependent kinase, which is activated 
by calcium [34], belonging to the serine/threonine kinase family [34, 35]. Elevated glucose 
levels increase the amounts of 1, 2~diacylglycerol (DAG), which is a lipid messenger, 
leading to the activation of PKC isoforms, causing blood flow alteration in the glomeruli of 
kidneys and eye retina [30, 34]. The effects of PKC activation in the progression of diabetic 
vascular complications include blood flow alterations, the thickening of the capillary 
basement membranes, as well as the expansion of the cellular matrix [30, 35].  
1.3.3The Polyol Pathway 
The polyol pathway occurs in two metabolic steps where glucose is converted to sorbitol by 
aldose reductase; and sorbitol to fructose by sorbitol dehydrogenase [30, 36]. Aldose 
reductase, catalyses the reduction of carbonyl compounds such as glucose, using up NADPH 
[36] resulting in the induction or exacerbation of oxidative stress, thus increasing 
hyperglycaemic damage [30, 36]. Sorbitol is oxidised to fructose by sorbitol dehydrogenase, 
using up NAD [30, 36]. Fructose is phosphorylated to fructose-3-phosphate, which is further 
broken down to 3-deoxyglucosone [30], which are important glycosylating agents that 
contribute to the formation of AGEs [36]. Polyol pathway activation alters cellular activity 
exposes cells to oxidative stress; and contributes  to diabetic retinopathy [36].  
1.3.4 The Hexosamine Biosynthesis Pathway 
The Hexosamine Biosynthesis Pathway (HBP) is the smaller branch of glycolysis [37], 
during which fructose-6-phosphate is converted to glucosamine-6-phosphate, by the enzyme 
glutamine:fructose-6-phosphate amidotransferase (GFAT) [37, 38]. Glucosamine-6-
phosphate is then converted to UDP (uridinediphosphate) N-acetyl glucosamine (UDP-
GlcNAc) [39, 40], which is used in lipid and protein glycosylation [40]. UDP-GlcNAc 





factors leading to ―pathologic gene expression changes‖ [39]. Activation of the HBP results 
in gene expression modification. This leads to of diabetic complications [30, 39, 40]. 
Although hyperglycaemia is said to be the earliest and first detectable sign of Diabetes 
Mellitus (DM), some metabolic errors of diabetes such as blood vessel dysfunction and 
defects in lipid metabolism are thought to cause alterations in the utilization of substrates, 
long before elevated sugar levels are detected. Furthermore, when there is a lack of insulin in 
diabetes mellitus, fatty acids stored in adipose tissue are released, resulting in free fatty acid 
(FFA) levels being increased. These FFA‘s then compete with glucose for storage in muscle, 
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Figure 1: Pathways that lead to diabetic complications include the polyol pathway, the 
hexasomine pathway, the protein kinase C pathway and the AGE pathway. Adapted from 




























1.4 Complications of diabetes mellitus 
1.4.1 Acute complications of diabetes – Diabetic Ketoacidosis (DKA) 
The persistence of hyperglycaemia leads to both acute and chronic complications. One of the 
major acute complications of diabetes is diabetic ketoacidosis [21]. Diabetic ketoacidosis 
(DKA) is defined as a complication that results in ketoacidosis and electrolyte imbalances 
[5], caused by a relative or absolute lack of insulin. This lack of insulin causes 
hyperglycaemia leading to dehydration and lipolysis [5, 41]. In diabetic ketoacidosis, 
deficiency in insulin, results in increases in catabolic hormones, that causes the over 
production of glucose and ketone bodies [8]. In renal tubes, excess glucose draws water, 
sodium, potassium, magnesium, calcium and other ions into the urine, from the circulation 
[5]. This osmotic diuresis is what results in dehydration and other electrolyte imbalances 
associated with diabetic ketoacidosis [5].  
DKA occurs more commonly in Type 1diabetic patients, and is said to be a major medical 
emergency, and still remains the number one cause of mortality in people with Type 1 
diabetes [8]. In patients unaware that they are diabetic, DKA occurs over several days, and as 
dehydration becomes more severe, the brain begins to experience an increase in osmolality 
[5, 7]. Mental disturbances then follow, beginning with weariness arising from metabolic 
acidosis [7]. Without treatment or if no care is provided, weariness becomes more severe and 
may eventually lead to coma [7]. While dehydration is usually the main presenting system of 
DKA, in some patients, it is acidosis rather than dehydration that is the main presenting 
system [7, 42, 43]. This often occurs in diabetic patients who are alert, however, with 
dyspnoea stimulated by acidosis; or in patients who consume large amounts of alcohol or fail 





The complications of diabetic ketoacidosis include cerebral oedema, acute respiratory distress 
syndrome and acute circulatory failure [8], and may lead to death if not treated. Clinically, 
95% of patients with DKA have normal total sodium levels and potassium, magnesium and 
phosphorous deficits are usually masked [5]. In DKA patients, the fasting serum glucose 
levels are usually greater than 25 mmol/L; occurring as a function of dehydration, which in 
itself may further elevate fasting serum glucose [7]. The management of diabetic ketoacidosis 
is multi-faceted, with patient education being very important. Treatments include fluid 
replacement therapy, and the administration of insulin [42, 43].  
1.4.2 Chronic complications of diabetes mellitus 
Chronic complications of diabetes are primarily vascular, made up of both microvascular and 
macrovascular complications [8]. These complications usually lead to morbidity and 
mortality, and occur late in diabetes (15-20 years) after diagnosis [5]. Microvascular 
complications of diabetes include retinopathy, nephropathy, peripheral and autonomic 
neuropathy as well as foot disease [8]. Macrovascular complications include coronary 
circulation, cerebral circulation, peripheral circulation [8]. Discussed in the following 
sections are the complications of diabetes mellitus.  
1.4.2.1 Diabetic Retinopathy 
Diabetic retinopathy is one of the leading causes of blindness, in adults between the ages of 
30 and 65, in developed countries [8, 41, 44], and occurs in all diabetes types [45]. This 
visual loss is associated with increased morbidity, which is often attributed to cardiovascular 
disease [44]. The severity of diabetic retinopathy ranges from background retinopathy 
(without maculopathy), which is mild to moderate non-proliferative [7, 8, 44].Background 
retinopathy has no immediate threat on vision [5, 8]. The next stage of diabetic retinopathy is 





pre-proliferative retinopathy, which is severe or non-severe non-proliferative; proliferative 
and finally advanced retinopathy [7, 44], which are all sight threatening [5, 8]. 
 In diabetic states, hyperglycaemia causes increased blood flow, directly affecting retinal 
endothelial cells and pericytes (cells that wrap around the endothelial cells of capillaries and 
venules throughout the body) [8]. The loss of retinal endothelial cells and death of pericytes 
results in changes in the integrity of the blood vessels of the retina, as well as impaired 
vascular auto regulation, such as altered blood retinal barrier [8, 41]. Uncontrolled retinal 
blood flow leads to endothelial cell proliferation, altered vascular permeability and an 
increased production of vasoactive substances; resulting in closure of capillaries [8, 41]. This 
then leads to retinal hypoxia (chronic), and the production of vascular endothelial growth 
factor (VEGF) is stimulated, which in turn stimulates endothelial cell growth [8]. Endothelial 
cell growth causes new vessel formation, as well as well increased vascular permeability, 
which leads to exudative damage [8, 41]. VEGF accomplishes this by acting via protein 
kinase C [8, 41].  
Clinically, the onset or background of diabetic retinopathy is characterised by features such 
as microaneurysms, haemorrhages, exudates, cotton wool spots, intra microvascular 
abnormalities, venous changes, as well as neovascularisation and ischemia [46]. 
Microaneurysms, haemorrhages and hard exudates are said to be the background of 
retinopathy, as their occurrence is very common in diabetic retinopathy [45].  
After diagnosis of diabetes, if good glycaemic control is maintained, diabetic retinopathy can 
be prevented [41], and the severity of the disease can be related to the quality of glycaemic 
control [5]. Hyperglycaemia is known to promote hyper-perfusion of the eyes; therefore a fast 
reduction of blood glucose may initiate deterioration of retinopathy, causing relative ischemia 





retinopathy is also a good preventive measure for all diabetes patients, but more so for those 
at risk of developing diabetic retinopathy [5, 7, 8]. Other measures to prevent diabetic 
retinopathy include maintenance of glycaemic control, however, avoiding stress caused by 
hypoglycaemic reactions, and the control of blood pressure [7].   
Both proliferative and non-proliferative retinopathies are treatable with retinal 
photocoagulation (condensation of protein material by the use of intense beam of light, in a 
controlled manner [5, 8]. Photocoagulation assists in the destruction of retinal ischaemia and 
reducing the production of growth factors such as VEGF [41]. Photocoagulation is also used 
as a seal for leaking microaneurysms, assists in the reduction of macular oedema and to 
obliterate new vessels on the retinal surface [8]. Tight diabetic and optimal blood pressure 
(BP) controls are known to reduce diabetic retinopathy and are among key treatments [7]. 
Furthermore, it is recommended that both Type 1 and Type 2 diabetics be examined for 
retinopathy every year [7, 41].  
1.4.2.2 Diabetic Nephropathy 
One of the leading causes of morbidity and death, and is a leading cause of end-of stage renal 
failure/disease (ESRF or ESRD) in developed countries[44]. Diabetic nephropathy occurs 
together with other microvascular as well as macrovascular complications of diabetes, and 
requires early intervention [8]. The progress and development of diabetic nephropathy is 
thought to be very complex because of the number of different cell populations found in the 
kidney and also because the kidney plays many different pathophysiological roles [41]. High 
glucose concentrations are the initiating factor, inducing several cellular effects, involving a 
diverse types of cells, such as endothelial cells, smooth muscle cells, masangial cells, 
podocytes (glomerular epithelial cells) and inflammatory cells [41]. Diabetic nephropathy 
risk factors include but are not limited to poor glycaemic control, hypertension [41, 44], as 





The factors that interplay in the pathogenesis of diabetic nephropathy include metabolic 
changes, hemodynamic changes [41, 44], as well as genetic and environmental factors [44]. 
Metabolically, serum AGE levels that occur as result of hyperglycaemia have been found in 
nephropathic kidneys [44]. Hemodynamic changes occur early in diabetic nephropathy and 
are often characterised by glomerular hyper-filtration [41, 44].  
One of the strongest determinants of glomerular hemodynamic changes and pressure is renal 
Angiotensin II (ANG II) [47]. ANG II is the principal factor in the renin-angiotensin system 
(RAS), which is the ―co-ordinated cascade of proteins and peptide hormones‖ [48]. In 
diabetic nephropathy, there is an increased production of ANG II within the kidney; in spite 
of the suppression of general RAS [48].This increased production of ANG II contributes to 
the exacerbation of diabetic nephropathy through a number of hemodynamic, tubular and 
growth promoting actions [48]. Clinically, diabetic nephropathy starts with the thickening of 
the glomerular basement membrane, and the accumulation of matrix material in the 
masangium [8]. This is followed by nodular deposits, and hardening of the glomerulus of the 
kidney (glomerulosclerosis) [8].  Eventually the glomeruli are lost and the function of the 
kidney declines.  
Upon symptoms and/or diagnosis of diabetic nephropathy, strategies to improve glycaemic 
control, reduce blood pressure and provide Angiotensin Converting Enzyme Inhibitor (ACE-
I), should be put in place to arrest progression [8]. ACE inhibitors appear to be more 
beneficial in controlling diabetic nephropathy than BP [8]. Angiotensin II receptor 
antagonists have been shown to yield the same results, but with additional risk of potassium 
increase in diabetic cardiomyopathy [8]. Although it comes with its own challenges, renal 





1.4.2.3 Diabetic Neuropathy 
Diabetic neuropathy is described as a disease that affects both the somatic and autonomic 
parts of the peripheral nervous system, however, there is evidence that the upper central 
nervous system and spinal cord are also affected in the long run [41]. Diabetic neuropathy 
occurs secondarily to metabolic disturbances and its prevalence is directly proportional to the 
extent of diabetes and glycaemic control [8, 49], although an early onset severity has been 
described [45]. There are two classes of diabetic neuropathies, namely diabetic 
polyneuropathy, where diabetes causes diffuse damage of the peripheral nervous system; as 
well mononeuropathy, where diabetes causes focal damage [49]. Symmetrical sensory 
polyneuropathy is the most common form of diabetic neuropathy [45], and its other forms 
include cranial, peripheral motor neuropathy and autonomic neuropathy [49]. Focal or 
mononeuropathies include Carpal Tunnel Syndrome (CTS) and Ulnar Neuropathy at the 
Elbow(UNE) [49]. Both polyneuropathy and mononeropathy play significant roles in sensory 
and motor deficits and are both associated with disability in patients [49]. Autonomic 
neuropathy which is not necessarily associated with peripheral somatic neuropathy [8], 
affects gastric and intestine the movement and activity, erectile function, function of the 
bladder, vascular tone and cardiac function [45].  
 
Diabetic neuropathy tends to occur early in diabetes and is often without symptoms in the 
majority of patients, but can cause major disability problems in others [50]. Pathologically, 
diabetic neuropathy manifests in the degradation of axons of myelinated and unmyelinated 
fibres, the thickening of Schwann cell basal lamina, demyelination that is segmented and 
patchy, as well as the thickening of the basal membrane and microthrombi in intraneural 
capillaries [8]. Endothelial enlargement with reduced oxygen and tension and hypoxia are 





Medications designed to inhibit the renin-angiotensin system as well as α1-antagonists are 
useful in improving nerve conduction velocities, resulting in increased neural blood flow 




















1.4.2.4 Macrovascular complications 
Diabetes increases the risk of cardiovascular events and deaths in affected individuals [45]. 
One of the main differentiating characteristics of cardiovascular events in diabetics as 
opposed to non-diabetics, is the higher frequency of coronary artery disease [51], due to 
elevated hyperglycaemia. Coronary artery disease tends to  occur at younger ages in diabetic 
individuals, especially in the presence of renal diseases [45]. More than 50% of all diabetics 
die from cardiovascular disease related diseases [52]. While the exact mechanisms that lead 
to cardiovascular disease are not fully understood, they involve the formation of 
atherosclerotic plaques or atherosclerosis, which leads to death in both type 1 and type 2 
diabetes [52, 53].  
A third of all diabetics develop aggressive complications, and more than 70% of all diabetics 
die of atherosclerotic-related diseases [52, 53]. Atherosclerosis is an inflammatory disease, 
characterised by the thickening of artery walls due to fatty material or lipid accumulation [54-
56]; and is related to and often leads to cardiovascular disease [54, 55]. This accumulation of 
lipids in the arteries affects the supply of the blood to the heart, brain as well as the lower 
parts of the body [30]; hence diabetic patients are at increased risks of strokes, heart attacks 
and lower limb amputations [30, 54, 55]. Endothelial dysfunction is hypothesised to be the 
first step in the progression of atherosclerosis  arising from hyperglycaemia, increased and 
oxidised low density lipoprotein (LDL) levels, genetic factors,  and free radicals [56].  
Atherosclerosis is not a distinct feature of diabetes mellitus, but is worsened by 
hyperglycaemia [45]. Insulin resistance and hyperglycaemia reduce the production of nitric 
oxide (NO) [30, 57], an important vasodilator of the endothelium [57]; and increase the 
proliferation of the vascular smooth muscle cells [30]. Vasodilation of the endothelium 
occurs when there is cholinergic input into the endothelial cells, activating NO synthase 





dysfunctional epithelium, acetylcholine acts on themuscurinic receptors on the smooth 
muscles, causing vasoconstriction [57].  
Responses that change the normal course of endothelial function are triggered, with 
endothelial permeability and adhesiveness, with respect to leucocytes and platelets, being 
increased [56]. A host of inflammatory responses are triggered, further thickening the artery 
wall. Macrophages and T-lymphocytes which are monocyte derived mediate these 
inflammatory responses [56]. Eventually the artery cannot compensate the dilation, allowing 
the lesion to intrude into the lumen and blood flow is altered [56, 57].  
Another common cause of injury or dysfunction of the endothelium and underlying smooth 
muscle is Low Density Lipoprotein (LDL) and lipoprotein modifications [28, 56]. When 
LDL‘s are trapped in the artery, they are engulfed by macrophages as oxidation progresses. 
This leads to the formation of cholesterol esters and lipid peroxides within the artery, 
resulting in the formation of foam cells. The vicious cycle of inflammation, lipoprotein 
modification and further inflammation, leading to the intrusion of the artery into the lumen 
and obstructing blood flow,  is maintained by the presence of these lipids in the artery [56]. 
All these result in the thickening of the endothelial basement membrane.  
The treatment of atherosclerotic events such as hypertension and hyperlipidaemia tends to 
have greater macrovascular impact in diabetic individuals, than glucose control [58]. This 
couldimply that the atherogenic effects observed in diabetic patients could be because of the 
macrovascular complications such as hypertension and dyslipidaemia, and not the impaired 





1.5 Diabetic dyslipidaemia 
While hyperglycaemia is thought to be the most significant feature in the progression of 
microvascular complications in diabetic patients, dyslipidaemia is an equally significant 
feature in the progression of macrovascular complications in diabetic patients [28]. 
Atherogenicdyslipidaemiais a common feature in diabetics, especially type 2 diabetics, and is 
defined by three main features; elevated Low Density Lipoprotein (LDL) cholesterol, 
decrease High Density Lipoprotein (HDL) cholesterol, as well as increased Very Low 
Density Lipoprotein(VLDL)-triglycerides in the blood, leading to cardiovascular disease [3, 
11, 28, 59, 60]. Predisposing features to atherogenicdyslipidaemia include obesity, the 
metabolic syndrome, insulin resistanceas well as alterations of insulin promoted fatty acids 
uptake in the skeletal muscle, and genetic factors [3, 52, 53, 59, 60]. 
The exact pathogenesis of diabetic dyslipidaemia is not known [61], but factors that are 
thought to be the probable causes include the effects of insulin on liver apoprotein 
production, regulation of Lipoprotein Lipase (LpL), the actions of insulin on adipose and 
muscle tissues; as well as the Cholesterol Ester Transfer Protein (CETP) actions [58]. 
Furthermore, these features are promoted by insulin resistance [28].  
In type 2 diabetes, insulin resistance is associated with elevated levels of insulin in serum, as 
well as in the decrease in the number of β-cells. This results in an altered regulation of 
lipoproteins in circulation, as well as altered glucose levels [28]. Fat cells that are insulin 
resistant release free fatty acids (FFA), leading to an increase in FFA‘s that enter the liver, 
promoting the production of triglycerides (TG) [61]. This inability of insulin to suppress the 
production of VLDL-triglycerides in the liver of patients with type 2 diabetes (as a result of 
insulin resistance), results in the increase of plasma TG levels [28, 61] and stimulates the 





blood stream increase, leading to an even greater degradation of stored triglycerides in 
adipose cells [59]. Increased levels of VLDL-triglycerides results in the reduction of HDL-C, 
as the triglycerides are transferred to HDL upon collision of these particles [28]. This 
reduction of HDL-C levels is followed by reduced anti-oxidant and anti-atherogenic 
activitiesof HDL [28, 61]. Furthermore, increased VLDL-triglycerides result in increased 
small dense LDL-C particles concentrations [28, 61], through the CETP action [58, 61]. 
When the LDL-C particles become smaller and denser, they become more susceptible to 
oxidation and are more readily invade the walls of arteries, contributing to atherosclerosis 
[28].  
Acyl-CoA: Cholesterol Acyltransferase (ACAT) and 3-hydroxy-3-methylglutaryl coenzyme 
(HMG-CoA) reductase are key enzymes in the regulation and synthesis of plasma 
cholesterol, respectively [62, 63]. ACAT is located in the rough endoplasmic reticulum of 
cells and occurs in two isoforms, ACAT-1 (expressed in most tissues) and ACAT-2 
(expressed mainly in the intestine and liver) [64]. ACAT is involved cholesterol 
esterification, cholesterol absorption as well as the accumulation of cholesterol in the arterial 
walls [65]. This accumulation is one of the main metabolic changes that occur in an 
atherosclerotic lesion [66] and the elevation of intestinal ACAT activity contributes to 
dyslipidaemia induced by diabetes [67]. HMG-CoA reductase is an endoplasmic reticulum-
bound, rate limiting enzyme in the biosynthesis of cholesterol [64, 68]. HMG-CoA regulates 
cholesterol metabolism as well as plasma cholesterol concentrations [68].  
1.5.1 Treatment of diabetic dyslipidaemia 
Treating diabetic dyslipidaemia is likely to reduce cardiovascular events in diabetic 
individuals by up to 50% [58], and the goal of therapy is the reduction of LDL-C levels, 
increasing of HDL and reduction of triglycerides [28]. The  American Diabetes Association 





cholesterol levels more than 45 mg/dL (1.15 mmol/L) as well triglycerides levels of no more 
than 200 mg/dL (2.3 mmol/L) [58]. This was modified in 2004 to target cholesterol levels of 
HDL > 40 mg/dL (1.0 mmol/L) in men and HDL 50 mg/dL (1.3 mmol/L) in women [69]; as 
well triglycerides levels < 150 mg/dL (1.7 mmol/L). Although LDL levels do not form part of 
the aberrations that lead to diabetic dyslipidaemia[11], LDL lowering recommendations are 
made on the observation that adult diabetics without any macrovascular disease, usually have 
the same propensity of developing cardiovascular disease as non-diabetic patients who have 
had cardiac event/s [58]. 
Attaining desired plasma lipoprotein and lipid levels often requires pharmacotherapy 
combined with lifestyle modifications (diet and exercise) [28, 61]. Dyslipidaemia is currently 
treated with lipid lowering agents, such as statins, niacin, ezetimibe, fibrates, nicotinic acid, 
bile acid sequestrants and omega-3 fatty acid [28, 61], in addition to good glycaemic control 
[28]. ACAT and HMG-CoA reductase inhibitors also play vital roles in lowering cholesterol 
levels as well as being anti-atherosclerotic agents [3, 63]. The common HMG-CoA reductase 









Table 1 A list of diabetic dyslipidaemia treatments, with their efficacy, adverse events and specific agents. Reproduced and   
             adapted from Mooradian, AD [61].   
Drug Efficacy  Adverse Effect Specific Agents    
Statins  LDL↓18-55% 
HDL↑5-15% 
TG↓7-30% 
Hepatoxicity, myopathy,  
↑creatine kinase levels 
Rosuvastatin; fluvastatin; simvastatin; pravastatin;   
atorvastatin; lovastatin, extended release lovastatin   
Ezetimibile LDL↓15-20% 
HDL↑1%   
TG↓8%     
No major adverse effects Ezetimibile 
Ezetimibile + Simvastatin LDL↓30-60% 
HDL↑9% 
TG↓20% 
Hepatoxicity, myopathy, ↑ 
creatine kinase levels 
10/10 mg to 10/80mg orally once daily 




Small dense LDL↓ 
Hot flashes, hyperglycaemia, 
hyperuricemia, hepatoxicity 
Nicotinic acid; extended release nicotinic acid;sustained 
release nicotinic acid 
Nicotinic Acid + Statin  LDL↓30-42%                                                  
HDL↑20-30%                                                              
TG↓32-44%                  
 
Hot flashes, hyperglycaemia,  
hyperuricemia, hepatoxicity ; 
myopathy, ↑ serum creatine                                                                                       
kinase levels 
Lovastatin and nicotinic acid; extended releasenicotinic 
acid and simvastatin 
Fibrates LDL↓5-20%                                                                              
HDL↑10-15%                                                                             
TG↓20-50%                                                
Small dense LDL↓ 
Dyspepsia, gallstones,
hepatoxicity, myopathy
Fenofibrate, micronized; fenofibrate; 
bezafibrate;gemfibrozil; modified-release bezafibrate 
Bile acids sequestrants LDL↓10-20%                                                                             




Colestyramine; colestipol hydrochloride;colesevelam 
hydrochloride.  
Omega-3 fatty acid  LDL↑5-10%                                                              
HDL↑1-3%                                                                     
TG↓25-30%                                         
Fishy aftertaste, 
gastrointestinal disturbances
Omega-3-acid ethyl esters; over the counter fish oil; 
dietary supplements containing omega-3 fatty acids; EPA 
and DHA 





1.5.2 Lipid lowering drugs 
Statins 
Statins are recommended as first-line pharmacological treatment for diabetic dyslipidaemia 
[61]. They have been shown to be effective in lowering LDL-C levels by 18-55%,  elevating 
HDL-C by 5-15%, and reducing TG levels by 7-30% [28, 61]. Their use is limited by side 
effects such as myopathy, gastrointestinal upsets, dose-dependent hepatoxicity and 
myotoxicity [28].  
Other lipid lowering Drugs  
 Other lipid lowering drugs used in the treatment of diabetic dyslipidaemia include   niacin, 
ezetimibe, fibrates, nicotinic acid, bile acid sequestrants and omega-3 fatty acid [61].The 
targeted goal of increasing HDL cholesterol levels to more than 40-50 mg/dL in diabetic 
patients, is more challenging than that of reducing LDL levels [58]; more so in patients with 
diabetic dyslipidaemia who sometimes report with HDL cholesterol levels of < 35 mg/Dl 
[58]. Niacin has been shown to be predominantly effective in raising HDL-C levels, with the 
ability of increasing HDL levels by up to 25%,  although higher doses of niacin may worsen 
hyperglycaemia [28]. 
Ezetimibe, is a selective ‗cholesterol absorption inhibitor‘ which has been shown to be highly 
effective in reducing LDL-C levels, especially in patients who cannot tolerate statins [28]. 
Fibrates have been shown to be effective in the lowering of TG and non HDL-C levels, while 
elevating HDL-C levels [28, 58]. The efficacy, adverse effects and specific agents and their 





1.5.3 Hypoglycaemic agents 
Some anti-diabetic agents are claimed to be having lipid lowering effects, more especially TG 
levels [28]. Metformin has been suggested to be an effective LDL-C, total cholesterol (TC) 
and TG lowering and an effective HDL-C elevating agent [28]. Pioglitazone, also an anti-
diabetic agent, has been shown to be effective in reducing TG levels and increase HDL-C 
levels [28].  While some of these agents may be effective as monotherapy, combination 
therapy may yield better outcomes [28].   
1.5.4 Combination therapy: lipid lowering and glucose lowering drugs 
An example of a highly effective combination therapy of lipid lowering and glucose lowering 
agents is that of drugs that control bile acids, which may have effect in the metabolism of 
both cholesterol and glucose levels [28]. Colesevelam hydrochloride, which is a bile-acid 
sequestrant, has a 10-20% LDL-C lowering effects when used alone [61], and 48%  when 
used in combination with statins, especially in patients with mild-moderate 
hypercholesterolemia [28]. The use of fibrates together with statins though is known to cause 
rhabdomyolysisand caution should always be taken when these are used [58]. These are, 
however, rarely used.  
For effective therapeutic outcome, treatments for dyslipidaemia should parallel good 







Figure 2: End-points associated with Diabetes Mellitus. Adapted from Wang et al., [70] 
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1.6 Treatment/s or management of diabetes mellitus 
Pharmacotherapy 
Type 1 diabetes is pharmacologically treated by the administration of sufficient amounts of 
exogenous insulin [24].If appropriate treatment is applied, it not only achieves euglycaemia 
but may also result in the desired effects of  insulin, such as the reversal of the breakdown of 
amino acidsand lipolysis in skeletal muscle and ketogenesis in the liver [21]. 
 The treatment of Type 2 diabetes is multi-faceted, since that its aetiology is also multi 
factorial [4]. Priority in type 2 diabetes treatment is lifestyle modifications. Obese patients 
should strive to reduce body weight, as well as exercise in order to increase insulin sensitivity 
[21, 24]. Pharmacological treatments for type 2 diabetes consist mainly of orally available 
treatments such as α-glucosidase inhibitors, sulfonylureas and meglitinides; as well as 
thiazolidinediones and biguanides [71, 72]. Metformin is the first-line treatment , but 
sometimes a combination of these drugs may be used for Type 2 diabetes patients [4]; 
however, some patients eventually require the administration of exogenous insulin [71]. 
1.6.1 Insulin therapy 
Type 1 and type 2 may need the exogenous insulin for treatment to reduce increased glucose 
levels [73]. Insulin promotes the uptake of glucose, amino acids and fatty acids. It also 
increases glycogen synthesis and storage in the liver from glucose [17]. Insulin therapy is 
initiated in patients who have severe hyperglycaemia, but glycaemic control could not be 
reached with two or more other treatments [73]. The different types of insulin include rapid-
acting (begins to work 15 minutes after injection), regular/short-acting (reaches blood stream 
30 minutes after injection), intermediate-acting (gets to work 2 hours after injection), and 
long-acting (which reaches blood the blood stream after several hours and lowers glucose 





is associated with fewer cases of hypoglycaemia and weight gain, compared to other 
treatments [75].  
1.6.2Intestinal glucose absorption inhibitors: α-glucosidase inhibitors 
Alpha glucosidase inhibitors, are also known as starch blockers, in relation to their ability of 
binding more tightly to α-glucosidase enzymes, in comparison to dietary carbohydrates[24]. 
Glucosidases function by cleaving to complex carbohydrates resulting in the release of 
glucose. α-Glucosidase inhibitors therefore increase time for the hydrolysis of carbohydrates 
by inhibiting these glucosidases [24, 72].α-Glucosidase inhibitors therefore reduce 
postprandialpeak of blood glucose, and are therefore very effective when taken with meals 
[21, 76].  They are, therefore, useful as treatment for postprandial hyperglycaemia as well as 
newly diagnosed patients with mild hyperglycaemia [24, 76]. The common side effects of α-
Glucosidase inhibitors include abdominal discomfort, bloating, flatulence and diarrhoea, 
which all result from gas released by bacteria that metabolise undigested carbohydrates that 
reach the large intestine [72, 76]. These side effects do, however, moderately become less 
severe and subside with continued treatment, but contraindicate these drugs in patients with 
inflammatory bowel disease bowel disease [21, 24].  
1.6.3 Insulin secretagogues 
The two most commonly used insulin secretagogues are sulfonylureas and meglitinides [21, 
24]. These drugs both stimulate and enhance the release of insulin from pancreatic β-cells, 
which results in increased circulating plasma insulin [24, 71]. Sulfonylureas function by 
inhibiting the K+/ATP channels of the β-cell [72], at the SUR 1 sub unit [21]. This results 
from the increased glucose metabolism causing β-cell accumulation of intracellular ATP, 
depolarization of the membrane, influx of Ca2+, as well as the fusion of the plasma membrane 
with vesicles containing insulinwhich gets secreted [72]. Sulfonylureas are generally safe, 





that they may cause hypoglycaemia and weight gain, hence are undesirable in obese patients 
[21, 72]. 
Meglitinides are very similar to sulfonylureas in their absorption and metabolism, as well as 
their side effects [21]. Furthermore, meglitinides stimulates the release of insulin by binding 
the SUR 1 subunit, inhibiting the β-cell K+/ATP channel; in a similar fashion as sulfonylureas 
[21, 72]. Although they yield the same results, these drugs bind to different parts of the SUR 
1 molecule [72]. 
1.6.4 Insulin sensitizers 
Insulin sensitizers increase the sensitivity of target tissues to insulin. The two most commonly 
used insulin sensitizers are thiazolidinediones and biguanides [71]. 
Thiazolidinediones (TZD) 
Peroxisome proliferator-activated receptor (PPAR)-γ agonists [thiazolidinedione (TZDs)] 
expand subcutaneous adipose tissue and secondarily reduce intra-myocellular lipids (IMCLs) 
and intra-hepatocellular lipids and insulin resistance [71, 72, 77]. These drugs do not affect 
the secretion of insulin (unlike insulin secretagogues), but rather enhance insulin effects on 
target tissues [21]. The nuclear hormone receptor, PPAR-γ is expressed in adipose tissues and 
is involved primarily in the differentiation of adipocytes [21, 77]. It has been shown that 
patients that have an over expression of PPAR-γ accumulate high levels of adipocyte markers 
when treated with TZDs. TZDs not only improve insulin sensitivity in adipose tissue, but also 
in the liver. The improvement of insulin sensitivity in the liver by TZDs is said to be a 
mystery considering that PPAR-γ is expressed in very minute levels in liver tissues. TZDs 
improve insulin sensitivity in adipose tissue, by causing changes in adipocyte gene 
expression, indicated by PPAR-γ, leading to changes in fat metabolism; and subsequently 





Type 2 diabetes, but are also beneficial in improving conditions that are associated with 
insulin resistance and hyperinsulinemia, such as polycystic ovarian syndrome [21, 72, 77]. 
Side effects of TZDs  include water retention, which may lead to oedema as well as 
cardiovascular risks [21].  
Biguanides 
Biguanides (metformin) function by increasing insulin sensitivity of target tissues, just like 
TZDs [21, 72, 77] and inhibit the breakdown of fatty acids, and inhibiting hepatic 
gluconeogenesis, hence promote glycolysis [24]. They achieve this by activating the AMP-
dependent protein kinase (AMPK)[21]. Metformin is the first line treatment for type 2 
diabetes and it is suggested that metformin prevents AGE formation and is also used in the 
treatment of Polycystic Ovary Syndrome (PCOS) [78].  
The most common side effects of metformin are those of mild gastrointestinal distress, 
which, however, are minimised by titration of the dosages [21, 72]. The other, more serious 
effect of metformin is lactic acidosis, which is however, low and predictable [72]. The 
precautions to be taken with the administration of metformin is that it should not be given to 
patients with heart failure, hypoxemia, respiratory disease, incidences of ketoacidosis, renal 
disease, severe infections as well as alcohol abuse [21]. Furthermore, metformin does not 
affect the secretion of insulin, hence is not associated with hypoglycaemia [72]. 
Other therapeutic interventions for Type 2 diabetes include incretinmimetics, glucagon-like 
peptide (GLP)-1 agonists and dipeptidyl peptidase (DPP)-4 inhibitors which increase insulin 





1.7 Medicinal plants 
Bioactive compounds in citrus fruits and juices are thought to have beneficial effects in 
diabetes mellitus and its related conditions, such as cardiovascular disease and dyslipidaemia.  
Citrus fruits are the most consumed fruits worldwide after mangoes, tomatoes and bananas 
[79]. Citrus fruits are known to contain phytochemicals and phenolics, which are thought to 
promote good health [79]. These phytochemicals and phenolics include flavonoids, flavones 
and flavanols, and have been shown to have anti-atherogenic, anti-inflammatory and 
antioxidant properties [55, 80-83]. The grapefruit is the most common citrus fruit and its 
consumption thought to induce hypoglycaemic effects, as well as improve lipid profiles in [3, 
84, 85]. 
1.7.1 The grapefruit 
C. paradise Macfad., commonly known as the grapefruit, originated in the West Indies, and 
has been recently introduced to many Pacific islands and other parts of the world [86]. In 
their study, de Moareset al., [87] reported that the grapefruit got its scientific name, C. 
Paradisi, from Macfadyen in 1830 in reference to a citrus tree known as ‗the forbidden fruit‘ 
in Jamaica.The grapefruit is one of the Citrus biotypes in which its hybrid origin and 
subsequent selection for mutants, is well documented [88]. Data from RAPD and SCAR 
markers indicate that the grapefruit was derived from the backcross between a sweet orange 
(C. sinensis) and pomelo (C. maxima/ C. grandis) [87-89].Grapefruit is commercially 
important as a crop not only because of its juice, but also because it is an important source of 
oils and pectin [87].  
The grapefruit and its juice are thought to play vital roles in the reduction of blood sugar 





diseases [85]. Regular consumption of grapefruit has been shown to be associated with weight 
loss, particularly in patients with the metabolic syndrome [89]. 
1.7.2 Bioactive constituents of grapefruit 
The major grapefruit pharmacologically active compounds include furanococoumarins 
(bergamottin and 6‘, 7‘ dihydroxybergamottin), as well as the flavonoids hesperidin, naringin 
and naringinin (Figure 3) [90]. Flavonoids are polyphenols present in abundance in fruits, 
vegetables and other plant materials [81, 91, 92]. Their primary role in plants is protection 
against injury, giving plants their colour, as well as function as antioxidants [83, 91].  
Upon consumption, naringin is digested and hydrolysed into naringenin, its aglycone, by 
intestinal bacteria [93, 94].  It is believed that naringenin, rather than naringin, is what bring 
about the reduction in blood sugar levels [85]. Naringenin is thought to reduce blood sugar 
levels by suppressing hepatic glucose production [95], as well by increasing muscle cell 
glucose uptake via AMPK [96].  
Other bioactive compounds present in grapefruit include limonoid aglycones, glucosides, 
ascorbic acid, folic acid, lucaric acid, carotenoids, pectin and potassium [85]. The number of 
bioactive compounds present in grapefruit and other fruits are have not been fully quantified 












































Figure 3: Chemical structures of some of the active polyphenolics present in grapefruit and 
grapefruit juices. a) Naringin, the most abundant flavoinoid in grapefruit that gives it its bitter 





1.7.3 Grapefruit juice-drug Interactions 
Grapefruit juice-drug interactions have been widely reported [88, 94].The inhibition of the 
intestinal cytochrome P450 3A4 (CYP3A4) enzyme (which metabolises many drugs) is the 
primary mode by which grapefruit interacts with drugs [90, 97]. Interaction of grapefruit 
juice with certain drugs causes a significant increase in the plasma concentrations of these 
therapeutic agents [85, 97]. The inhibition of CYP3A4 is irreversible and the 
inhibited/inactivated enzyme is destroyed [85, 97]; resulting in high oral availability of drugs 
that are metabolised by this enzyme [85, 90, 97]. Grapefruit juice interacts only with the 
intestinal and not hepatic CYP3A4 [97], and therefore only affects orally and not 
intravenously administered drugs [85, 97]. Grapefruit juice also inhibits other cytochrome 
P450 enzymes [85], and drug transporters such as P-Glycoprotein (P-gp) and Organic Anion-
Transporting Protein (OATP) [85, 94]. Some of the cardiovascular drugs that are also 
substrates of P-gp are simvastatin, lovastatin, carvedilon and veramapil [85].  
 
Clinical significance of GFJ-drug interactions is not fully understood. Many diabetic patients 
routinely consume GFJ in anticipation of improved outcome. However, the effects of GFJ 
consumption on the glycaemic index and lipid profile in a diabetic state have not previously 






1.8 Hypothesis, aims and objectives 
1.8.1 Hypothesis 
Grape fruit juice improves glycaemic index and lipid profile in a diabetic state.  
1.8.2 Aim 
To investigate the anti-diabetic and anti-dyslipidaemic effects of grapefruit juice in induced 
type-1 diabetes  
1.8.3 Objectives 
i. To establish a diabetic rat model  
ii. To investigate hypoglycaemic effects of grapefruit juice in a diabetic state 
iii. To investigate anti-dyslipidaemic effects of grapefruit juice in a diabetic state  











Materials and Methods 
2.1 Materials 
2.1.1 Chemicals and reagents 
Chemicals and reagents were sourced as indicated below.  
Regular insulin, normal saline, portable glucometers and glucose test strips (Bayer AG, 
Leverkusen, Germany); and were purchased from a local pharmacy. Reagents and chemicals 
purchased from Sigma-Aldrich were as follows: D-Glucose, streptozotocin, citrate and 
phosphate buffers, EDTA, anthrone, H2SO4, glucose-6-phosphatase, molybdic acid, sodium 
docecylsulphate (SDS), ascorbic acid, HEPES, KCl, dithiothreitol, MgCl2, inositol 
diphosphate (IDP), NADH, phosphoenolpyruvate, Na2CO3and malate dehydrogenase. The 
primary antibodies, HMG-CoA reductase (C-1) mouse monoclonal antibody (to be diluted 
1:1000), insulin receptor substrate 1 rabbit polyclonal antibody (IRS1; to be diluted 1:1000), 
and ACAT-2 (N-15) goat polyclonal antibody (to be diluted 1:1000) were purchased from 
Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). The secondary antibodies Horse 
Radish-conjugate goat anti-mouse and horseradish peroxidase-conjugate mouse anti goat 
antibody were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). The 
Biomedical Research Unit (BRU) of the University of KwaZulu-Natal provided Halothane 
and other accessories.  
Grapefruit juice used was purchased from a local Woolworths Store, and it was declared to 
have the following nutritive contents:  190 kJ of energy, 0.6 g of protein, 10.0 g carbohydrate 





preservatives or additives used in the preparation of this grapefruit juice, according to the 
manufacturer‘s declaration.  
2.2 Animal treatment and ethical clearance 
Male Wistar Rats (Rattusnovergicus) of 200-300 g body weight (BW) provided by the 
Biomedical Research Unit were randomly assigned into five groups, (n=6). The animals were 
given free access to standard commercial chow and tap water ad libitum, and kept under 
maintained laboratory conditions of 25 ±2ºC temperature and 55% ±5% humidity. Water 
consumption by animals was assessed by measuring amounts of water left in drinking bottles 
at the end of each day. The animals were maintained at a 12-hour dark-to-light cycle, from 
8:00 to 20:00 daily, and they were handled humanely, according to the guidelines prescribed 
by the Biomedical Research Ethics Committee of UKZN, which also granted ethical 
clearance/approval for this study (reference 106/13/Animal, see Appendix I).  
2.2.1 STZ, GFJ and insulin treatment 
Animals from Group 1, which were the controls, were treated with 3.0 ml/kg of body weight 
of distilled water by oral gavage. Similarly, Groups 3 and 4 were treated with 3.0 ml/kg body 
weight of GFJ. Diabetes was induced in groups 2, 4and 5by 60.0 mg/kg body weight single 
intraperitoneal injection of streptozotocin (STZ), dissolved in 0.2 mL of 0.1 M citrate buffer, 
pH 4.5 [98]. STZ treatment was performed after an overnight starvation of animals. Group 5 
was further treated with regular insulin (4U/kg subcutaneously, twice a day). Three days after 
STZ was administered, blood glucose concentrations were measured by tail pricking, to 
confirm the development of diabetes. Rats with random blood glucose levels less than 11 
mmol/L were considered non-diabetic, hence excluded from the study or re-induced [5, 7, 9]. 
On treatment day 60, animals were sacrificed by halothane overdose by placing them in an 





LTD,SA) for 3 minutes (each animal); and blood samples were collected by cardiac puncture. 
Plasma was frozen in a Bio Ultra freezer (Snijers Scientific, Holland, -80 °C) until used for 
different assays. Rat livers were excised, weighed, rinsed in normal saline and stored in liquid 
nitrogen (-180ºC) for further analysis of glycogen content and hepatic enzymes.  
Table 2 Animal treatment protocol.GFJ (grapefruit juice); STZ (streptozotocin); D60 (STZ 
60 mg/kg BW); GFJ-ND (GFJ-Non-diabetic); GFJ-D60 (GFJ + STZ 60 mg/kg BW); Ins-D60 
(Insulin + STZ 60 mg/kg BW). 
  Treatment 












1 Control 3.0    3.0 
2 D60    60.0 3.0 
3 GFJ-ND  3.0   3.0 
4 GFJ-D60  3.0  60.0 3.0 
5 Ins-D60   4.0 60.0 3.0 
 
2.3 Experimental methods 
2.3.1 Glucose monitoring 
Fasting blood glucose (FBG) tests were performed on days 0 and 59 of treatment. The 
Glucose Tolerance Test (GTT) was done on treatment day 59. Droplets of blood obtained by 
means of tail pricking were mounted on glucose test strips and blood glucose analysed using 
a portable glucometer (Ascensia Elite™, Bayer Schering Pharma, Germany), using the 





and GTT were performed. For the GTT, blood glucose concentrations were determined by 
tail pricking following intra-peritoneal injection of 3.0 g/kg body weight of glucose, in 
normal saline. Blood glucose levels were then monitored and analysed at time intervals of 0, 
15, 30, 60 and 90 minutes, for all treatment groups. Area under the curve (AUC) was 
calculated from blood glucose-time curves and presented as AUC units (mM x minutes).  
2.3.2 Plasma insulin 
An ultra-sensitive rat insulin enzyme-linked immunoassay kit (DRG Diagnostics, Marburg, 
Germany) was used to analyse the plasma insulin levels, according to the manufacturer‘s 
manual/protocol. Samples of 25 µl were and 100 µl of enzyme conjugate were added on a 96-
well plate, and incubated on a plate shaker (900 rmp) at 25 ºC for 2 hours. The plate was then 
washed with 700 µl of wash buffer. This was done 6 times. Thereafter, 200 µl of substrate 
tetramethylbenzidine (TMB) was added into each well and incubated at 25 ºC for 15 minutes. 
Stop solution (15 µl) was then added to each well and incubated for 5 minutes on a plate 
shaker, after which optical density was measured in a microplate reader (EZ Read 400, 
biochrom®) at 450 nm.  
2.3.3 Hepatic glycogen 
Hepatic glycogen content was measured by the modified method of Seifter et al., [99]. The 
liver tissues were homogenised using 5 volumes of 4 M KOH (ice cold). The homogenate 
was then dissolved by boiling in a water bath (100° C) for 30 minutes. The glycogen was 
then precipitated with ethanol, thereafter pelleted, washed, and solubilized in distilled water. 
Treatment with anthrone reagent followed to assay the glycogen concentration of the livers 
(92 g/L anthrone in 95% (v/v) H2SO4), and the absorbance measured at 620 nm. Glycogen 






2.3.4 Hepatic enzymes 
Glucokinase activity 
Glucokinase activity in the livers of different treatment groups was determined by 
spectrophotometric methods that had been previously described by Davidson and Arion [100] 
and Barzila and Rosetti [101]. Liquid nitrogen frozen livers were aliqouted into tubes (100 
mg/ tube) and homogenated in buffer containing: 50 mM HEPES, 100 Mm KCl, 2.5 
mMdithiothreitol, 1 mM EDTA and 5 mM MgCl2. The resulting homogenates were then 
centrifuged at 100,000 g for 60 minutes at 4oC. The supernatant was used for 
spectrophotometric measurements, while the microsomal residue was kept for use in the 
glucose-6-phosphatase assay. The Bradford assay [102] was performed to determine protein 
concentrations. Glucose-6-phosphatase formation from glucose was coupled to oxidation by 
glucose-6-phosphate dehydrogenase and NAD+ in a reaction mix containing the following: 50 
mM HEPES, 100 mMKCl, 2.5 mMdithiothreitpl, 7.5 mM MgCl2, 5 mM ATP, 10 mg/ml 
albumin and glucose of six different concentrations (0, 5, 10, 15, 25, 50 mM, respectively). 
Also in the reaction mix were 0.5 mM NAD+, 4 units of glucose-6-phosphate dehydrogenase, 
from a fermentation associated bacteria (Leuconosticmesenteroides), and 1 mg (wet weight) 
of liver. ATP was added to the mixture to initiate the reaction and NAD+ reaction rate was 
recorded at 340 nm for half an hour, at the tempearature of 37oC. A Beckman DU-70 
spectrophotometer with an internal temperature controller was used. Enzyme activity was 
expressed as µmol/g liver protein protein/minute.   
Glcose-6-phosphatase (G6Pase) activity 
Liver samples (100 mg) that were previously frozen in liquid nitrogen were aliqouted into 
tubes. Buffer containing the 50 mM-HEPES, 100 mM-KCl, 2.5mM-dithiothreitol, 1 mM-





were then centrifuged at the speed of 100, 000 x g for 60 minutes, at 4oC, to get the residual 
microsomal fraction. Glucose-6-phosphatase liver content by the modified 
spectrophotometric method of Lange et al., [103]. Total content protein was determined by 
the Bradford method [102]. The microsomal fraction was then incubated in three different 
concentrations of glucose-6-phosphate (0, 0.5, 1.0, 2.5, 5 and 10 mM). This reaction was 
carried out at 37oC and after 30 minutes stopped with a solution containing the following 
reagents: acid molybdate, with 2/9 volumes of 10% SDS, and 1/9 volume of 10% ascorbic 
acid. This mix was then incubated at 45oC for 20 minutes, and the absorbance recorded at 820 
nm. A Beckman DU-70 spectrophotometer with a temperature controller was used to 
measure the absorbance. The basis of this assay was the hydrolysis of glucose-6-phosphate by 
the microsomal fraction containing glucose-6-phosphatase. A standard curve was drawn 
using the different concentrations of free phosphate, and glucose-6-phosphatase enzyme 
activity expressed in µmol/min/g of liver protein.  
Phosphoenolpyruvate carboxykinase (PEPCK) activity 
PEPCK activity was determined as per the modified methods of Bentle and Lardy [104] and 
Stiffin et al. [105]. Cytosolic fraction was obtained from homogenised liver tissues by 
centrifugation at 100,000 g for 1.0 hr at 4°C, and the activities of enzymes measured in a 
final reaction volume of 1.0 ml, at pH 7.0, containing 50 mM-sodium HEPES/KOH buffer, 
10.0 mM-IDP, 1.0 mM-MgCl2, 1.0 mM-dithiothreitol, 0.25 mM-NADH, 2.0 mM-
hosphoenolpyruvate, 50 mM-Na2CO3 and 10 U of malic dehydrogenase (1 unit defined as 1 
µmol of malate produced/min/mg of liver protein). Total protein content was determined by 
Bradford method [102]. All assay components were pre-incubated for 3 minutes. The enzyme 
activity was measured at 25°C and 340 nm, using Beckman DU-70 spectrophotometer 
equipped with temperature controller, and expressed as mmol of oxaloacetate (OAA) 





2.3.5 Plasma lipids 
An automated chemistry analyser (Labmax 240) was used to analyse fasting total cholesterol, 
HDL cholesterol and triglycerides, using commercial kits purchased from ACE Chemicals 
Ltd. (Seoul, South Korea). The HDL fractions were separated by the heparin-manganese 
procedure as previously described [106], while the LDL cholesterol was calculated according 
to the Friedwald formula: LDL = total cholesterol – (HDL cholesterol + VLDL cholesterol 
[107]. VLDL was calculated as VLDL = triglycerides/5 [108]. The atherogenic index was 





2.3.6 Western blot analysis: ACAT and HMG-CoA reductase 
Protein Extraction  
Liquid nitrogen frozen hearts and livers were homogenised in ice-cold Tris-sucrose buffer 
(100 mmol/L Tris, 250 mmol/L sucrose at pH 7.6), using a motor driven Teflon glass 
homogeniser at 504 x g, in the presence of complete protease inhibitor cocktail. The 
homogenate was then ultra-centrifuged, at 100 000 x g for 60 minutes, at 4ºC. The pellet was 
then re-suspended in HEPES-sucrose buffer (10 mmol/L HEPES, 300 mmol/L sucrose, pH 
7.5, protease inhibitor). Total protein content was then determined using the Bradford Assay 
[102].  
Western Blot Analysis  
Protein samples (50µg) were separated using 12.5% SDS–PAGE for 60 minutes at 120 V in a 
tank buffer (Electrode Buffer – X1), using the Mini-Protean 3 cell (Bio Rad) system. The 
PageRulerTMprestained protein ladder (Fermentas, Thermo Scientific) was used as a 
molecular weight marker. The PAGE gel was then transferred onto a nitrocellulose 
membrane (AmershamTMHybondTMnitrocellulose membrane, GE Healthcare) at room 
temperature for 60 minutes, at 100 V, in a transfer buffer, with cooling. The nitrocellulose 
membranes were then blocked for one hour using 6% (w/v) skim milk in Tris-buffered saline 
with tween for 60 minutes at room temperature, with agitation, to block non-specific binding 
of the primary antibody. This nitrocellulose membrane, after being rinsed twice with Tris-
buffered saline, was then incubated overnight at 4ºC with the primary antibody overnight. 
The nitrocellulose membrane was then rinsed six times for ten minutes each to remove non-
specifically bound primary antibody.  The nitrocellulose membrane was then probed with 
horseradish peroxidise labelled secondary antibodies, at room temperature for an hour. The 





each, to remove any unbound secondary antibodies. The nitrocellulose membrane was then 
visualised using the Immn-StarTMHRPChemiluminescent kit (Bio Rad) on the ChemiDocTM 
XRS system, with Image LabTMsoftware (Bio Rad).  
The primary antibodies used were HMGCR (C-1) mouse monoclonal antibody (to be diluted 
1:1000), ACAT-2 (N-15) goat polyclonal antibody (to be diluted 1:1000) and β-actin as the 
reference protein (to be diluted 1:2000). The secondary antibodies used were horseradish 
peroxidise-goat anti mouse and horseradish peroxidase-conjugate mouse anti-goat antibodies 
for the HMGCR and ACAT-2, respectively.  
2.3.7 Statistical analysis 
The data are presented as mean ± standard deviation and analysed by the One-way ANOVA 
or the non-parametric Mann-Whitney tests and/or student t-tests were applied to the results to 
determine statistical significance, using Graph pad Prism Software Version 5.0. (Graphpad 












3.1 Weights and water Consumption 
In comparison to the controls, diabetic rats had significantly (p<0.05) reduced weights. 
Treatment of diabetic with insulin or with grapefruit juice significantly (p<0.05) improved 
the weights of the diabetic animals (Figure 4). There was a significant (p<0.05) increase in 
average water consumption among the diabetic groups in comparison to the control. 
Treatment with grapefruit juice significantly (p<0.05) reduced or improved water intake 








Figure 4: Total body weight differences in animals before and after treatment.  * P<0.05 
compared to control, ^ P<0.05 compared to D60, # P<0.05 compared to D60. Ins-D60, 
insulin and diabetic, 60 mg/kg; GFJ-ND, grapefruit juice and non-diabetic; GFJ-D60, 











































Figure 5: Average daily water consumption by animals over a 60 day treatment. * P<0.05 
compared to the control, ^ P<0.05 compared to D60, # P<0.05 compared to D60. Ins-D60, 
insulin and diabetic, 60 mg/kg; GFJ-ND, grapefruit juice and non-diabetic; GFJ-D60, 
grapefruit juice and diabetic, 60 mg/kg; D60, diabetic, 60 mg/kg. 
3.2 Glucose monitoring 
Fasting blood glucose concentrations were significantly (p<0.05) increased in diabetic 
animals in comparison to the controls. Grapefruit juice treatment, resulted in a significant 
(p<0.05) reduction in fasting plasma glucose levels compared to the diabetic non-treated 
group (Figure 6). Diabetic rats displayed impaired glucose tolerance, while treatment with 




















































































Figure 6: Concentrations of fasting blood glucose of animals on the 59th day of treatment. No 
insulin was administered before test.  * P<0.05 compared to the control, ^ P<0.05 compared 
to D60, # P<0.05 compared to D60. Ins-D60, insulin and diabetic, 60 mg/kg; GFJ-ND, 
grapefruit juice and non-diabetic; GFJ-D60, grapefruit juice and diabetic, 60 mg/kg; D60, 










































Figure 7: Glucose Tolerance Tests after 0, 15, 30, 60 and 90 minute intervals of treatment 
(A), and AUCs calculated as explained in the methods (B). *P<0.05 compared to control; 
^P<0.05 compared to D60.Ins-D60, insulin and diabetic, 60 mg/kg; GFJ-ND, grapefruit juice 










































3.4 Plasma insulin 
Controls and non-diabetic grapefruit juice treated animals exhibited similar fasting plasma 
insulin levels, which were, however, significantly (p<0.05) reduced in diabetic animals. 
Diabetic insulin (Ins-D60) treated animals had significantly (p<0.05) higher fasting plasma 
insulin levels in comparison to diabetic grapefruit (GFJ-D60) and diabetic control (D-60) 
animals, respectively. There was no significant elevation in fasting plasma insulin levels 








































Figure 8: Fasting plasma insulin. Insulin treatment was withheld on test day. *P<0.05 
compared to the control, #P<0.05 compared to D60. Ins-D60, insulin and diabetic, 60 mg/kg; 
GFJ-ND, grapefruit juice and non-diabetic; GFJ-D60grapefruit juice and diabetic, 60 mg/kg; 
D60, diabetic, 60 mg/kg. 
3.5 Hepatic glycogen 
Diabetic non-treated animals (D60) appeared to have reduced glycogen content compared to 
the controls (Figure 9). Diabetic animals treated with GFJ had significantly elevated (p 






































Figure 9:Liver glycogen content concentrations of the different treatment groups. * P<0.05 
compared to control, ^P<0.05 compared to D60, # P<0.05 compared to GFJ-D60. Ins-D60, 
insulin and diabetic, 60 mg/kg; GFJ-ND, grapefruit juice and non-diabetic; GFJ-D60, 





3.6 Glucokinase activity 
When plotted against substrate concentrations, hepatic glucokinase activity obeyed The 
Michaelis-Menten kinetics (Figure 10). Linear regression analysis of Eadie-Hofstee plots 
[100], (Table 3) showed a significant (p<0.05) reduction in glucokinase activity in diabetic 
rats (Vmax, 13.4 (D60) µmol/g of liver tissue/ min); when compared to the control (Vmax; 
16.8 µmol/g of liver tissue/ min)rats. In comparison to non-treated rats, treatment with GFJ 
alone, {Vmax; 14.5µmol/g of liver tissue/ min (GFJ-D60); insulin alone {Vmax; 20.3 µmol/g 
of liver tissue/ min (Ins-D60); significantly increased glucokinase activities (p<0.05). GFJ 
treatment resulted in a similarly significant (p<0.05) increaseinglucokinase activity in non-
diabetic animals compared to controls. 


























Figure 10: Michaelis-Menten kinetics of glucokinase activity in the livers of treated rats. 
Glucokinase activity was plotted against substrate concentrations. Ins-D60, insulin and 





diabetic, 60 mg/kg; GFJ-Ins-D60, grapefruit juice and insulin combination, and diabetic, 60 
mg/kg; D60, diabetic, 60 mg/kg. 
Table 3 Calculated glucokinase activity as determined by Eadie-Hofstee plots. Statistically 
significant differences are marked by relevant symbols applicable to different treatment 
groups. Vmax = (µmol/g of liver tissue/min). * P<0.05 compared to D-60; λ P<0.05 
compared to GFJ-ND; + P<0.05 compared to Ins-D60; ^P<0.05 compared to GFJ-D60.  
 Control D60 GFJ-ND GFJ-D60 Ins-D60 
Mean + SD Mean + SD Mean + SD Mean + SD Mean + SD 
Vmax 16.8 +/- 0.4 13.4 +/- 0.3 23.0 +/- 0.9 14.5 +/- 0.3 20.3 +/- 0.4 
Km (mM) 0.27 0.281 0.21 0.35 0.37 
r2 0.9107 0.9276 0.8971 0.8703 0.8937 
Vmax/ Km 4.5 3.7 4.9 5.1 7.4 






3.7 Glucose-6-phosphatase activity 
Glucose-6-phosphatase activity, similarly obeyed Michaelis-Menten kinetics when plotted 
against substrate concentrations (Figure 11).  The linear regression of data transformed 
inEadie-Hofstee [100] plots (Table 4) showed that Glucose-6-phosphotase activities were 
significantly (p< 0.05) increased in diabetic {Vmax: 22.6 (D60) µmol/min/g liver tissue; 
Vmax/Km:102.0 (D60) in comparison to the controls (Vmax: 12.5 µmol/min/g liver tissue; 
Vmax/Km:53.39) (Table 3). Subsequent treatment with either GFJ alone {Vmax; 18.8 (D60) 
µmol/min/g liver tissue; Vmax/Km: 96.56 (D60)} or insulin alone (Vmax: 18.0 µmol/min/g 
liver tissue, Vmax/Km: 56.62), resulted in a significant (p<0.05) decrease in Glucose-6-
phosphatase activity diabetic compared to non-treated diabetic D60, animals (Table 3). 
Glucose-6-phosphatase activity in GFJ-treated non-diabetic rats (Vmax: 11.8µmol/min/g 
liver tissue; Vmax/Km: 48.48) was similar to that of the controls.  




























Figure 11:Michaelis-Menten kinetics of glucose-6-phosphatase activity in the livers of rats 





Ins-D60, insulin and diabetic, 60 mg/kg; GFJ-ND, grapefruit juice and non-diabetic; GFJ-
D60, grapefruit juice and diabetic, 60 mg/kg; D60, diabetic, 60 mg/kg. 
Table 4 Calculated G6Pase activity as determined by Eadie-Hofstee plots. Statistically 
significant differences are marked by relevant symbols applicable to different treatment 
groups. Vmax = (µmol/g of liver tissue/min). *P<0.05 compared to D60; +P<0.05 compared 
to Ins-D60; ^P<0.05 compared to GFJ-D60.  
 
 
Control D60 GFJ-ND GFJ-D60 Ins-D60 
Mean + SD Mean + SD Mean + SD Mean + SD Mean + SD 
Vmax 12.5 +/- 0.3 22.6 +/- 0.4 11.8 +/- 0.3 18.8 +/- 0.3 18.0 +/- 0.5  
Km (mM) 
4.61 4.520 4.12 5.13 3.15 
r2 0.7253 0.7577 0.7356 0.8702 0.8265 
Vmax/ Km 
57.39 102.0 48.48 96.56 56.62 







3.8 Phosphoenolpyruvate carboxykinase (PEPCK) activity 
Similarly PEPCK activity Michaelis-Menten kinetics when plotted against substrate 
concentrations (Figure 12). Linear regression analysis of Eadie-Hofstee plots [100], (Table 5) 
showed significantly (p<0.05) increased PEPCK activity in diabetic animals [Vmax: 22.6±0.6 
(D60) μmol/min/g liver tissue; Vmax/Km: 102.0 (D60)] compared to controls (Vmax: 12.5 
+/- 0.3;Vmax/Km: 57.39). Treatment of diabetic rats with GFJ [Vmax: 18.8 +/-0.3 (GFJ-
D60) μmol/min/g liver tissue; Vmax/Km: 96.56 (GFJ-D60)] significantly (p<0.05) reduced 
PEPCK activity in diabetic rats. Similarly, treatment with insulin (Vmax: 18.0 +/- 0.5 
μmol/min/g liver tissue, Vmax/Km: 56.62) significantly (p<0.05) reduced PEPCK activity in 
diabetic rats compared to non-treated diabetic rats (Table 5). 
 
































Figure 12: Michaelis-Menten kinetics of phosphoenolpyruvatecarboxykinaseactivity. 





insulin and diabetic, 60 mg/kg; GFJ-ND, grapefruit juice and non-diabetic; GFJ-D60, 
grapefruit juice and diabetic, 60 mg/kg. 
Table 5: Calculated PEPCK activity as determined by Eadie-Hofstee plots. Statistically 
significant differences are marked by relevant symbols applicable to different treatment 
groups. Vmax = (µmol/g of liver tissue/min). *P<0.05 compared to D60; +P<0.05 compared 
to Ins-D60; ^P<0.05 compared to GFJ-D60.  
 
Control D60 GFJ-ND GFJ-D60 Ins-D60 
Mean + SD Mean + SD Mean + SD Mean + SD Mean + SD 
Vmax 
12.5 +/- 0.3 22.6 +/- 0.6 11.8 +/- 0.3 18.8 +/- 0.3 18.0 +/- 0.5 
Km (mM) 
4.61 4.520 4.12 5.13 3.15 
r2 
0.7253 0.7577 0.7356 0.8702 0.8265 
Vmax/ Km 
57.39 102.0 48.48 96.56 56.62 
P<0.05 * *, +, ^  ^  + 
 
3.9 Plasma lipid profiles 
In comparison to the non-treated diabetic group (D60), the total plasma cholesterol levels 
were significantly (p<0.05) higher in the grapefruit juice treated diabetic group (Figure 13). 
HDL-cholesterol levels were also higher in the diabetic grapefruit juice treated group versus 
the diabetic non treated group (p<0.05) (Figure 14). Conversely, LDL-cholesterol levels were 
significantly higher in the diabetic non treated group in comparison to the control group 































Figure 13: Total cholesterol (TC) levels of different treatment groups. *P<0.05 compared to 
D60. Ins-D60, insulin and diabetic, 60 mg/kg; GFJ-ND, grapefruit juice and non-diabetic; 































Figure 14: HDL-cholesterol levels of the different treatment groups. *P<0.05 compared to 
D60. Ins-D60, insulin and diabetic, 60 mg/kg; GFJ-ND, grapefruit juice and non-diabetic; 




























Figure 15: LDL-cholesterol levels of the different treatment groups. LDL calculated as LDL 
= total cholesterol – (HDL cholesterol + VLDL cholesterol). * P<0.05 compared to the 
control, ^ P<0.05 compared to D60. Ins-D60, insulin and diabetic, 60 mg/kg; GFJ-ND, 
grapefruit juice and non-diabetic; GFJ-D60 grapefruit juice and diabetic, 60 mg/kg; D60, 
diabetic, 60 mg/kg. 
3.8 Atherogenic index 
The atherogenic index, calculated as LDL to HDL ratios (LDL:HDL) was significantly 
(p<0.05) higher in the non-treated diabetic compared to the control group (Figure 16). The 
grapefruit juice treated diabetic and the insulin treated diabetic groups had significantly 
(p<0.05, respectively) reduced atherogenic indexes compared to the non-treated diabetic 

















Figure 16: Atherogenic Index (LDL:HDL ratio) of the different treatment groups.  * P<0.05 
compared to the control, ^ P<0.05 compared to D60, # P<0.05 compared to D60. Ins-D60, 
insulin and diabetic, 60 mg/kg; GFJ-ND, grapefruit juice and non-diabetic; GFJ-D60 
grapefruit juice and diabetic, 60 mg/kg; D60, diabetic, 60 mg/kg. 
3.8 Hepatic cholesterol synthesis: ACAT and HMG-CoA reductase 
Animals from the non-treated diabetic group had significantly elevated ACAT enzyme 
expression in rat livers compared to the control (Figure 17A and 17B). Grapefruit juice-
treated diabetic animals (GFJ-D60) had significantly (p<0.05) reduced ACAT enzyme 
expression in comparison to non-treated diabetic animals (Figure 17A and 17B). Similarly, 
animals from the insulin-treated diabetic group had significantly reduced liver ACAT enzyme 
expressions (Figure 17A and 17B). Animals from the non-treated diabetic group had 
significantly (p<0.05) elevated hepatic HMG-CoA reductase enzyme expression in compared 





























(p<0.05) reduced hepatic HMG-CoA reductase enzyme expression compared to the non-














Figure 17A): Immuno-reactive bands reflecting the liver enzyme ACAT in liver tissues of 
rats. Ins-D60, insulin and diabetic, 60 mg/kg; GFJ-ND, grapefruit juice and non-diabetic; 
GFJ-D60, grapefruit juice and diabetic, 60 mg/kg; D60, diabetic, 60 mg/kg, n=6.B) Hepatic 
ACAT expression relative densities for the different treatment groups. # P<0.05 compared to 
D60, * P<0.05 compared to the control, ^ P<0.05 compared to D60. Ins-D60, insulin and 
diabetic, 60 mg/kg; GFJ-ND, grapefruit juice and non-diabetic; GFJ-D60, grapefruit juice and 
















































Figure 18A): Immuno-reactive bands reflecting the liver enzyme HMG-CoA reductase in the  
liver tissues of rats. Ins-D60, insulin and diabetic, 60 mg/kg; GFJ-ND, grapefruit juice and 
non-diabetic; GFJ-D60, grapefruit juice and diabetic, 60 mg/kg; D60, diabetic, 60 mg/kg, 
n=6. B): Hepatic HMG-CoAreductase expression relative densities for the different treatment 
groups.# P<0.05 compared to D60, * P<0.05 compared to the control, ^ P<0.05 compared to 
D60. Ins-D60, insulin and diabetic, 60 mg/kg; GFJ-ND, grapefruit juice and non-diabetic; 
GFJ-D60, grapefruit juice and diabetic, 60 mg/kg; D60, diabetic, 60 mg/kg. 
 
 








































This study was aimed at investigating the anti-diabetic and anti-dyslipidaemic effects of 
grapefruit juice in type 1 STZ-induced diabetic rats. The findings suggest that GFJ does have 
glucose lowering and lipid profile improving effects on diabetic rat models. Although 
grapefruit juice treatment did not result in significant LDL-C level changes, the anti-
dyslipidaemic effects of grapefruit juice were suggested by the down regulation of hepatic 
enzymes ACAT and HMG-CoA reductase. These results are significant in that they highlight 
and contextualise GFJ and/or its bioactive chemical constituents as having hypoglycaemic 
and anti-dyslipidaemic effects.  
4.1 Hypoglycaemic effects of Grapefruit Juice 
Treatment of animals with 60 mg/kg body weight of STZ appears to have resulted in the 
destruction of beta cells, leading to the induction of type 1, insulin dependent diabetes in the 
animals. The diabetic animals had significantly (p<0.05) reduced weight gain (or increased 
weight loss) during normal growth (compared to the control), suggesting accelerated lipid 
and protein breakdown in the absence of insulin (D60). Treatment with grapefruit juice 
and/or insulin resulted in a significant (p<0.05) improvement in weight loss among the 
diabetic animals (Figure 4). This suggests that treatment with grapefruit juice or insulin has 
the ability to prevent and reduce proteolysis, as well as lipolysis; which are associated with 
the deficiency of insulin. However, these treatments do not affect natural growth in non-
diabetic animals.  
Diabetic animals had significantly (p<0.05) higher water consumption in comparison to the 





(p<0.05) reduced water consumption in diabetic animals (Figure 5). The reduction in water 
consumption demonstrated by diabetic animals treated with grapefruit juice suggests that 
grapefruit juice has polydipsia and polyuria reducing effects.   
Fasting blood glucose levels of STZ-induced diabetic rats were significantly (p<0.05) higher 
than those of the controls (Figure 6), suggesting loss of beta cells functionality and the 
absence of insulin after treatment with 60 mg of STZ. STZ [2-deoxy-2(3-methyl-3-
nitrosoureido)-D-glucopyranose] is a broad spectrum antibiotic that was initially extracted 
from Streptomyces acromogens [98, 109, 110], which was first reported to have diabetic 
effects in rats, mice and other mammals back in 1963 [98, 109, 110]. STZ is thought to exert 
its diabetic effects by the degranulation of β-cells through reactive oxygen species (ROS) 
[109]. The results therefore suggest that type 1 diabetic models were successfully created.  
Treatment of diabetic animals with insulin (Ins-D60) significantly (p<0.05) reduced fasting 
blood glucose levels, compared to non-treated animals (D60). Treatment with grapefruit juice 
(GFJ-D60) similarly significantly (p<0.05) reduced fasting blood glucose levels in 
comparison to non-treated diabetic rats (D60). This indicates that GFJ has hypoglycaemic 
effects similar to those of insulin. Diabetic rats exhibited impaired glucose tolerance in GTT 
(Figure 7A) and calculated AUCs (Figure 7B) showed that treatment with significantly 
(p<0.05) improved glucose intolerance in diabetic rats. Hypoglycaemic effects of grapefruit 
juice in non-diabetic animals has been reported [84]. However, the effects of grapefruit juice 
in conditions of hyperglycaemia have not previously been shown. Although diabetics widely 
consume grapefruit juice in hope for improve diabetes, this study suggests that grapefruit 





4.2 Effects of grapefruit juice on plasma insulin levels 
Diabetic rats (Ins-D60, GFJ-D, and D60) had significantly reduced plasma insulin levels in 
comparison to non-diabetic rats (Figure 8). The significantly reduced plasma insulin levels of 
STZ-induced diabetic rats can be attributed to the destruction of β-cells by STZ, and hence 
reduced plasma insulin levels [109]. Treatment with grapefruit juice of diabetic animals 
(GFJ-D) did not significantly increase plasma insulin levels in comparison to non-treated 
diabetic animals (Figure 8); neither did treatment with GFJ of non-diabetic rats affect plasma 
insulin levels, in comparison to the controls. This suggests that grapefruit juice and/or its 
bioactive compounds do not enhance insulin production/secretion, nor does it repair damaged 
pancreatic β-cells. The non-insulinotropic effects of grapefruit juice have been previously 
reported [84].  
4.3 Effects of grapefruit juice on hepatic glycogen content 
Non-treated diabetic animals (D60) had significantly (p<0.05) reduced liver glycogen levels 
compared to the controls (Figure 9). Treatment of diabetic and non-diabetic rats with 
grapefruit juice (GFJ-D60 and GFJ-ND) significantly increased glycogen levels compared 
non-treated diabetic and the control group rats, respectively (Figure 9). This suggests that 
treatment with grapefruit juice promotes glycogen synthesis. GFJ could possibly achieve this 
by suppressing insulin counter-regulating hormones. Alternatively, grapefruit juice treatment 
could also exert glycogen synthesis by activating the mitogen activated protein kinase 
signalling pathways, resulting in the phosphorylation of protein phosphatase-1, which 
activates glycogen synthase; leading to the synthesis of glycogen.  
4.4 Grapefruit juice effects on glucokinase, G6Pase and PEPCK activity 
Glucokinase is an enzyme responsible for the conversion of glucose into glucose-6-phosphate 
[7]. In this study, glucokinase activity was significantly reduced in diabetic non-treated (D60) 





and insulin treatment significantly (p<0.05) improved glucokinase activity of the animals, in 
comparison to diabetic non-treated animals (Table 3). Furthermore, the treatment of non-
diabetic rats with grapefruit juice significantly (p<0.05) compared to the controls; and far 
more than the insulin treated diabetic animals. 
G6Pase functions by regulating the rate-limiting step in gluconeogenesis (the hydrolysis of 
glucose-6-phosphate from glycogen) [111], thus contributing to elevated glucose levels. In 
this study, G6Pase activity was significantly reduced by GFJ treatment. Jung et al., [112] 
have reported that the bio-active components of grapefruit juice, naringin and hesperidin 
reduce blood glucose levels in mice by elevating glucokinase and glycogen concentrations, 
and concomitantly suppressing G6Pase.  
PEPCK regulates the rate-limiting steps in hepatic gluconeogenic flux by converting 
oxaloacetate to phosphoenolpyruvate and carbon dioxide, respectively [111]. Diabetic 
animals displayed significantly (p<0.05) increased PEPCK activity compared to the controls 
(Figure 12 and Table 5). Treatment with grapefruit juice as well as with insulin significantly 
(p<0.05) reduced PEPCK enzyme activity in diabetic animals compared to the non-treated 
diabetic animals.  
The study did not demonstrate how grapefruit juice increases the activity of glycolytic 
glucokinase, resulting in increased hepatic synthesis, nor did it demonstrate whether 
grapefruit juice suppresses gluconeogenic enzymes by either increasing cellular protein 
content or gene transcription. However, considering that GFJ treatment was chronic in these 
animals, and the similarity between GFJ and insulin effects, the enhancement of gene 
expression of these cannot be ruled out. The effects of GFJ juice seem to be enhanced by 
insulin, and it is tempting to speculate that GFJ, could, like metformin, be up regulating the 
―master energy sensor‖ (AMPK) which in turn could be activating glucokinase and 





short-term or increased gene expression in the long-term. While the anti-diabetic effects of 
flavonoids are well documented [95], grapefruit juice as opposed to pure forms of isolated 
flavonoids was chosen for this study. This was on the basis of evidence suggesting naringin 
does not exert hypoglycaemic effects in type 1 diabetic model [3], suggesting that insulin is 
required for hypoglycaemic effects of flavonoids and by extension GFJ as demonstrated in 
the present study. 
4.5 Plasma lipids profiles 
The key goal of treating dyslipidaemia is focused on reducing LDL-cholesterol and TG  
levels, as well as increasing HDL-cholesterol levels [28, 113]. Non-treated diabetic rats had 
significantly elevated LDL-cholesterol levels compared to the controls (Figure 14), 
suggesting diabetic dyslipidaemia. Grapefruit juice treatment of diabetic rats (GFJ-D60) 
significantly (p<0.05) increased total cholesterol levels as well as HDL (p<0.05) levels, in 
comparison to non-treated diabetic rats (D60) (Figures 12 and 13 respectively). The observed 
increase in total cholesterol levels by grapefruit juice treatment can thus be attributed to the 
increase in HDL-cholesterol fraction. Atherogenic index, expressed as LDL:HDL ratio, was 
significantly (p<0.05) higher in non-treated diabetic rats in comparison to the controls. The 
effects of grapefruit juice treatment of diabetic animals seemed to be similar to those exerted 
by insulin in improving the atherogenic index (Figures15). This study suggests that treatment 
with grapefruit juice has anti-dyslipidaemic effects.  
4.6 Hepatic cholesterol synthesis 
The results of our study show that ACAT and HMG-CoA reductase protein expression were 
significantly elevated in non-treated diabetic animals (D60) in comparison to the diabetic 
grapefruit juice-treated animals (GFJ-D60) as well as the controls (Figure 17a and 17b). 
ACAT is an important cholesterol-regulating enzyme that is involved in cholesterol 





of LDL-cholesterol, as well as the accumulation of the fatty material in the arterial wall, 
which is one of the important metabolic changes in the progression of atherosclerosis [63]. 
The down regulation of ACAT protein expression by grapefruit juice treatment of diabetic rat 
models resembles that of known ACAT inhibitors [63], suggesting that grapefruit juice 
and/or its active compounds have ACAT have cholesterol-lowering and anti-atherosclerotic 
activity. HMG-CoA reductase also functions as a rate limiting enzyme in the cholesterol 
biosynthetic pathway [3, 68, 114]. The common HMG-CoA reductase inhibitors include 
statins such as simvastatin [3]. The effects of grapefruit juice in the expression of the enzyme 
HMG-CoA in diabetic rat models resemble those of HMG-CoA inhibitors. This is suggestive 
of statin-like effects of grapefruit juice in cholesterol metabolism. 
4.7 Conclusion 
This study was aimed at investigating the anti-diabetic and anti-dyslipidaemic effects of 
grapefruit juice in STZ-induced diabetic rat models. A type-1 diabetic rat model was 
successfully established, and the findings of the study indicate that indeed the administration 
of grapefruit juice does have anti-diabetic and anti-dyslipidaemic effects in STZ-induced 
diabetic rat models. The study suggests that grapefruit juice results in anti-diabetic effects by 
promoting glycogen synthesis, improving glucokinase activity, reducing G6Pase activity, as 
well as by reducing PEPCK enzyme activity. The anti-dyslipidaemic effects of grapefruit are 
suggested to occur by the elevation of HDL-C levels, improvement of the atherogenic index 
as well as through the down regulation of hepatic enzymes ACAT and HMG-CoA reductase.  
The management of diabetes mellitus and dyslipidaemia with GFJ may not only be associated 
with improving these diseases, but may also be associated with preventing and easing these 





4.8 Shortfalls of Study 
While this study did indicate the potential beneficial effects of grapefruit juice administration 
in the treatment of diabetes mellitus and diabetic dyslipidaemia; it did not show the bioactive 
chemical constituents of the grapefruit that are responsible for the observed effects, as 
individual bioactive chemical constituents were not extracted and tested.  
4.9 Future recommendations 
-  The effects of grapefruit should also be studied in type 2 diabetic rat models and effects 
compared to observed in type 1 diabetic rat models 
- Methods that highlight the mechanism of action of grapefruit juice should be taken into 
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